The George Institute for Global Health, Sydney, Australia.
University of New South Wales, Sydney, Australia.
Intensive Care Med. 2018 Aug;44(8):1249-1257. doi: 10.1007/s00134-018-5274-x. Epub 2018 Jun 27.
To determine differences in health-related quality of life (HRQoL), survival and healthcare resource use of critically ill adults with and without sepsis.
We conducted a primary propensity score matched analysis of patients with and without sepsis enrolled in a large multicentre clinical trial. Outcomes included HRQoL at 6 months, survival to 2 years, length of ICU and hospital admission and cost of ICU and hospital treatment to 2 years.
We obtained linked data for 3442 (97.3%) of 3537 eligible patients and matched 806/905 (89.0%) patients with sepsis with 806/2537 (31.7%) without. After matching, there were no significant differences in the proportion of survivors with and without sepsis reporting problems with mobility (37.8% vs. 38.7%, p = 0.86), self-care (24.7% vs. 26.0%, p = 0.44), usual activities (44.5% vs. 46.8%, p = 0.28), pain/discomfort (42.4% vs. 41.6%, p = 0.54) and anxiety/depression (36.9% vs. 37.7%, p = 0.68). There was no significant difference in survival at 2 years: 482/792 (60.9%) vs. 485/799 (60.7%) (HR 1.01, 95% CI 0.86-1.18, p = 0.94). The initial ICU and hospital admission were longer for patients with sepsis: 10.1 ± 11.9 vs. 8.0 ± 9.8 days (p < 0.0001) and 22.8 ± 21.2 vs. 19.1 ± 19.0 days, (p = 0.0003) respectively. The cost of ICU admissions was higher for patients with sepsis: A$43,345 ± 46,263 (€35,109 ± 35,043) versus 34,844 ± 38,281 (€28,223 ± 31,007), mean difference $8501 (€6885), 95% CI $4342-12,660 (€3517 ± 10,254), p < 0.001 as was the total cost of hospital treatment to 2 years: A$74,120 ± 60,750 (€60,037 ± 49,207) versus A$65,806 ± 59,856 (€53,302 ± 48,483), p = 0.005.
Critically ill patients with sepsis have higher healthcare resource use and costs but similar survival and HRQoL compared to matched patients without sepsis.
确定患有和不患有败血症的重症成人患者在健康相关生活质量(HRQoL)、生存和医疗资源使用方面的差异。
我们对一项大型多中心临床试验中患有和不患有败血症的患者进行了主要倾向评分匹配分析。结果包括 6 个月时的 HRQoL、2 年的生存率、ICU 和住院时间以及 2 年的 ICU 和住院治疗费用。
我们获得了 3537 名符合条件的患者中 3442 名(97.3%)的链接数据,并对 905 名(97.3%)败血症患者中的 806 名与 2537 名(29.5%)无败血症患者中的 806 名进行了匹配。匹配后,有和没有败血症的幸存者报告在移动能力(37.8% vs. 38.7%,p = 0.86)、自我护理(24.7% vs. 26.0%,p = 0.44)、日常活动(44.5% vs. 46.8%,p = 0.28)、疼痛/不适(42.4% vs. 41.6%,p = 0.54)和焦虑/抑郁(36.9% vs. 37.7%,p = 0.68)方面存在问题的比例没有显著差异。2 年生存率无显著差异:482/792(60.9%)vs. 485/799(60.7%)(HR 1.01,95%CI 0.86-1.18,p = 0.94)。败血症患者的初始 ICU 和住院时间更长:10.1 ± 11.9 天 vs. 8.0 ± 9.8 天(p < 0.0001)和 22.8 ± 21.2 天 vs. 19.1 ± 19.0 天(p = 0.0003)。败血症患者的 ICU 入院费用更高:A$43,345 ± A$46,263(€35,109 ± €35,043)vs. 34,844 ± A$38,281(€28,223 ± €31,007),平均差异 A$8501(€6885),95%CI A$4342-12,660(€3517 ± 10,254),p < 0.001,2 年总住院治疗费用也更高:A$74,120 ± A$60,750(€60,037 ± €49,207)vs. A$65,806 ± A$65,806(€53,302 ± €48,483),p = 0.005。
与匹配的无败血症患者相比,患有败血症的重症患者的医疗资源使用和成本更高,但生存率和 HRQoL 相似。